Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Jonathan Licht named president, chief scientific officer at Van Andel Institute









